Edward M. MD Kaye - Sep 4, 2025 Form 4 Insider Report for Stoke Therapeutics, Inc. (STOK)

Role
Director
Signature
/s/ Jonathan Allan, Attorney-in-Fact
Stock symbol
STOK
Transactions as of
Sep 4, 2025
Transactions value $
$0
Form type
4
Date filed
9/5/2025, 04:10 PM
Previous filing
Sep 2, 2025
Next filing
Sep 30, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kaye Edward M. MD Director C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD /s/ Jonathan Allan, Attorney-in-Fact 2025-09-05 0001522780

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction STOK Employee Stock Option (Right to Buy) Disposed to Issuer $0 -179K -82.64% $0.00 37.5K Sep 4, 2025 Common Stock 179K $8.33 Direct F1, F2
transaction STOK Restricted Stock Units Disposed to Issuer $0 -144K -100% $0.00 0 Sep 4, 2025 Common Stock 144K Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction represents a disposition to the Issuer of equity securities that is exempt pursuant to Rule 16b-3(e) and 16b-6(d). The equity award was partially canceled for no consideration by mutual agreement of the reporting person and the Issuer.
F2 The option began vesting on April 15, 2025. Pursuant to the terms of the initial grant, the original number of shares subject to the option vests in ratable increments monthly and the option shall be fully vested on December 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.
F3 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
F4 The reported transaction represents a disposition to the Issuer of equity securities that is exempt pursuant to Rule 16b-3(e) and 16b-6(d). The entire equity award was canceled for no consideration by mutual agreement of the reporting person and the Issuer.
F5 Pursuant to the terms under which it was granted, the award was scheduled to vest as to 1/4 of the total award annually beginning on March 15, 2026, subject to the reporting person's continued service to the Issuer through each vesting date.